The head of an Indian company contracted to make AstraZeneca Plc's Covid vaccine said it could deliver it to health care workers and elderly Indians by January as the country's caseload of infections crossed nine million on Friday.
The health minister stressed that Ukraine is cooperating on all possible global initiatives to ensure that Ukrainians receive the vaccine as soon as possible after it is registered.
The researchers said that two doses of CoronaVac at different concentrations and using different dosing schedules had goof tolerance and moderately immunogenic in healthy adults aged between 18-59 years.
"We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".
They are also testing whether the vaccine stops people developing Covid-19 in larger, phase three trials.
Besides the recipients of the Sinopharm jabs, authorities in Zhejiang said they had made a COVID-19 vaccine developed by the privately owned pharmaceutical company Sinovac Biotec available to high-risk groups in the east China province under the emergency use scheme.
Prof Andrew Pollard, study lead from the University of Oxford, told the BBC he was "absolutely delighted with the results" showing a strong immune response "even in those over 70 years of age".
The trial involved 560 adult volunteers, with 240 of them over the age of 70. It is also generating a good antibody response.
Responses were "similar" across all age groups, the researchers said.
"The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement.
WATCH | How well will COVID-19 vaccines work in the real world?
A Chinese Foreign Ministry spokesman Zhao Lijian told a media briefing on Wednesday that five Chinese vaccine candidates are under clinical trials in countries, including the UAE, Brazil, Pakistan and Peru, and phase one and phase two clinical trials of some other vaccines are accelerated.
In September, the Department of Health requested at least 12.9 billion pesos (258 million dollars) for the initial purchase of the vaccines, storage facilities and other requirements.